REAL-WORLD EVIDENCE IN REGULATORY APPROVALS: LEGAL FRAMEWORK, EVIDENTIARY STANDARDS AND JUDICIAL ACCOUNTABILITY

1. INTRODUCTION

Real-World Evidence (RWE) refers to clinical evidence concerning the use, benefits, risks, and effectiveness of medical products derived from the analysis of Real-World Data (RWD). Such data may originate from electronic health records, hospital databases, disease registries, insurance claims, patient-monitoring systems, observational studies, and post-marketing surveillance.

Regulatory authorities increasingly consider RWE when evaluating pharmaceutical products, vaccines, medical devices, biological medicines, and gene therapies. It can supplement conventional clinical trial evidence, support additional indications, evaluate long-term safety, and identify adverse effects that may not become apparent during controlled clinical trials.

However, using RWE in regulatory approvals creates important legal concerns involving data reliability, patient consent, privacy, scientific validity, selection bias, transparency, and regulatory accountability.

2. LEGAL AND REGULATORY FRAMEWORK

A. REGULATORY EVIDENCE REQUIREMENTS

Regulatory authorities must determine whether submitted evidence sufficiently establishes product quality, safety, and efficacy. RWE may supplement clinical trial evidence, but its acceptance depends on the applicable statutory framework and the nature of the regulatory application.

B. DATA PROTECTION AND PATIENT PRIVACY

Real-world datasets frequently contain sensitive medical information. Their collection and processing must comply with applicable privacy legislation, confidentiality obligations, consent requirements, and lawful data-processing standards.

C. SCIENTIFIC RELIABILITY

Evidence must demonstrate adequate data quality, completeness, representativeness, and methodological reliability. Confounding variables, missing information, inconsistent medical records, and selection bias must be appropriately addressed.

D. REGULATORY TRANSPARENCY

Manufacturers and applicants should disclose data sources, study protocols, analytical methods, limitations, and potential conflicts of interest so that regulatory authorities can independently evaluate the evidence.

E. POST-MARKETING SURVEILLANCE

RWE can support continuing safety monitoring after approval. Regulatory authorities may use emerging evidence to reassess product safety, impose additional conditions, or take other appropriate regulatory measures.

3. MAJOR LEGAL AND PUBLIC SAFETY CONCERNS

A. UNRELIABLE CLINICAL DATA

Incomplete or inaccurate hospital records may produce misleading conclusions about treatment effectiveness and adverse reactions.

B. SELECTION AND CONFIRMATION BIAS

Datasets may disproportionately represent particular populations, creating misleading conclusions when findings are generalized to the wider population.

C. PRIVACY VIOLATIONS

Unauthorized collection, sharing, or commercialization of patient information can violate privacy and data-protection requirements.

D. INSUFFICIENT CAUSAL EVIDENCE

Observational associations do not automatically establish that a medical product caused a particular outcome. Confounding factors must be considered before regulatory conclusions are reached.

E. UNDERREPRESENTATION OF VULNERABLE POPULATIONS

Evidence drawn from limited healthcare populations may fail to reflect the safety and effectiveness of products in children, older persons, pregnant individuals, or people with uncommon medical conditions.

F. PREMATURE REGULATORY APPROVAL

Overreliance on insufficiently validated RWE may result in approval decisions that are not adequately supported by scientific evidence, potentially exposing patients to avoidable risks.

4. IMPORTANT CASE LAWS AND JUDICIAL PRINCIPLES

Direct reported judgments specifically establishing the admissibility of RWE in drug approvals remain limited. The following decisions provide relevant direct regulatory or analogous principles concerning evidence, scientific decision-making, patient rights, and pharmaceutical safety.

1. Novartis AG v. Union of India (2013) 6 SCC 1 — Direct pharmaceutical regulatory authority.

The Supreme Court examined the patentability of an improved pharmaceutical substance under Section 3(d) of the Patents Act, 1970. The judgment emphasized the importance of demonstrating enhanced therapeutic efficacy rather than relying merely on assertions of pharmaceutical improvement. Its significance for RWE lies in the need for credible scientific evidence when therapeutic benefits are claimed.

2. A.P. Pollution Control Board v. Prof. M.V. Nayudu (1999) 2 SCC 718 — Analogous scientific-evidence authority.

The Supreme Court emphasized the importance of scientific expertise in regulatory decision-making involving complex technical questions. The judgment supports the use of competent scientific assessment when evaluating medical datasets and evidence submitted to regulatory authorities.

3. K.S. Puttaswamy v. Union of India (2017) 10 SCC 1 — Direct privacy authority.

The Supreme Court recognized informational privacy as an aspect of the fundamental right to privacy under Article 21. This principle is relevant to the collection, processing, sharing, and secondary use of patient health information for generating RWE.

4. Samira Kohli v. Dr. Prabha Manchanda (2008) 2 SCC 1 — Analogous patient-consent authority.

The Supreme Court explained the legal requirements of informed consent in medical treatment. Its principles are relevant when patient information is collected or used for research and clinical evidence generation, subject to applicable research and data-protection requirements.

5. Donoghue v. Stevenson (1932) AC 562 — Analogous product-safety authority.

The House of Lords established the manufacturer's duty of care towards ultimate consumers. The principle supports accountability where inadequate evaluation or defective medical products cause foreseeable injury.

6. Daubert v. Merrell Dow Pharmaceuticals, Inc. (1993) 509 U.S. 579 — Comparative scientific-evidence authority.

The United States Supreme Court established standards for assessing the reliability and relevance of expert scientific testimony. Its discussion of scientific methodology provides useful comparative guidance when evaluating the reliability of evidence, although it is not a direct ruling on regulatory approval of RWE.

7. United States v. Rutherford (1979) 442 U.S. 544 — Direct comparative drug-regulatory authority.

The United States Supreme Court considered the FDA's statutory authority concerning unapproved drugs. The judgment demonstrates that therapeutic claims and patient need do not automatically remove the requirement to satisfy applicable drug-approval standards.

5. PREVENTIVE AND REGULATORY COMPLIANCE MEASURES

Regulatory authorities and pharmaceutical applicants should adopt the following safeguards:

Establish documented standards for RWD collection and verification.

Ensure appropriate patient consent or another lawful basis for data processing.

Use reliable and representative healthcare datasets.

Apply scientifically appropriate statistical and epidemiological methods.

Identify confounding factors, selection bias, and missing information.

Maintain independent review of clinical evidence.

Protect patient identities and confidential medical records.

Maintain transparent research protocols and analytical documentation.

Conduct post-approval safety monitoring using relevant RWE.

Require additional clinical evidence where observational findings are insufficient to establish safety or efficacy.

6. INDIAN REGULATORY POSITION

In India, the Drugs and Cosmetics Act, 1940, and New Drugs and Clinical Trials Rules, 2019, provide the principal statutory framework for new-drug approvals and clinical trials. The Central Drugs Standard Control Organisation (CDSCO) supervises relevant regulatory processes.

RWE may support regulatory assessment where permitted by the applicable requirements, but it should not automatically be treated as a substitute for mandatory clinical trial evidence. The Digital Personal Data Protection Act, 2023, also provides an important privacy framework for digital personal data, subject to its applicable commencement and implementation provisions.

7. CONCLUSION

Real-World Evidence has significant potential to improve regulatory decision-making by providing information about medical products under ordinary healthcare conditions. Nevertheless, its use must be supported by reliable datasets, scientifically appropriate methodologies, patient privacy safeguards, and independent regulatory assessment.

Indian constitutional principles, pharmaceutical legislation, and judicial decisions concerning scientific evidence, informed consent, and product safety provide an important foundation for responsible RWE governance. Ultimately, RWE should strengthen evidence-based approvals rather than weaken established standards of patient safety, scientific integrity, and regulatory accountability.